Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Stopped Withdrawn \[This study was terminated early by Wyeth, prior to dosing any subjects, for business reasons not related to safety.

Conditions

• Opioid-Induced Constipation

Interventions

• DRUG: methylnaltrexone
• DRUG: placebo

Sponsor

Bausch Health Americas, Inc.

Collaborators

• [object Object]